164 related articles for article (PubMed ID: 20840743)
1. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain.
Diaz A; Diez M; Bleda MJ; Aldamiz M; Camafort M; Camino X; Cepeda C; Costa A; Ferrero O; Geijo P; Iribarren JA; Moreno S; Moreno ME; Labarga P; Pinilla J; Portu J; Pulido F; Rosa C; Santamaría JM; Telenti M; Trapiella L; Trastoy M; Viciana P
BMC Infect Dis; 2010 Sep; 10():267. PubMed ID: 20840743
[TBL] [Abstract][Full Text] [Related]
2. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City.
Li J; Munsiff SS; Tarantino T; Dorsinville M
Int J Infect Dis; 2010 Apr; 14(4):e292-7. PubMed ID: 19656705
[TBL] [Abstract][Full Text] [Related]
3. Incidence of tuberculosis in HIV-infected patients in Spain: the impact of treatment for LTBI.
Martínez-Pino I; Sambeat MA; Lacalle-Remigio JR; Domingo P;
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1545-51. PubMed ID: 24200266
[TBL] [Abstract][Full Text] [Related]
4. Treatment of latent tuberculosis infection in HIV infected persons.
Akolo C; Adetifa I; Shepperd S; Volmink J
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD000171. PubMed ID: 20091503
[TBL] [Abstract][Full Text] [Related]
5. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma SK; Sharma A; Kadhiravan T; Tharyan P
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
[TBL] [Abstract][Full Text] [Related]
6. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
[TBL] [Abstract][Full Text] [Related]
7. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and adherence to treatment for latent tuberculosis infection in patients with hematologic malignancies.
Sánchez-García EM; Gamallo R; Blanco-Moure A; Viejo MA; Amador L; Anibarro L
Infection; 2013 Oct; 41(5):903-7. PubMed ID: 23737388
[TBL] [Abstract][Full Text] [Related]
9. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
Johnson JL; Okwera A; Hom DL; Mayanja H; Mutuluuza Kityo C; Nsubuga P; Nakibali JG; Loughlin AM; Yun H; Mugyenyi PN; Vernon A; Mugerwa RD; Ellner JJ; Whalen CC;
AIDS; 2001 Nov; 15(16):2137-47. PubMed ID: 11684933
[TBL] [Abstract][Full Text] [Related]
10. A prospective cohort study of latent tuberculosis in adult close contacts of active pulmonary tuberculosis patients in Korea.
Park SH; Lee SJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Kim HJ; Menzies D
Korean J Intern Med; 2016 May; 31(3):517-24. PubMed ID: 27052266
[TBL] [Abstract][Full Text] [Related]
11. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Swindells S; Ramchandani R; Gupta A; Benson CA; Leon-Cruz J; Mwelase N; Jean Juste MA; Lama JR; Valencia J; Omoz-Oarhe A; Supparatpinyo K; Masheto G; Mohapi L; da Silva Escada RO; Mawlana S; Banda P; Severe P; Hakim J; Kanyama C; Langat D; Moran L; Andersen J; Fletcher CV; Nuermberger E; Chaisson RE;
N Engl J Med; 2019 Mar; 380(11):1001-1011. PubMed ID: 30865794
[TBL] [Abstract][Full Text] [Related]
12. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
13. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Whalen CC; Johnson JL; Okwera A; Hom DL; Huebner R; Mugyenyi P; Mugerwa RD; Ellner JJ
N Engl J Med; 1997 Sep; 337(12):801-8. PubMed ID: 9295239
[TBL] [Abstract][Full Text] [Related]
14. Acceptability of treatment of latent tuberculosis infection in newly HIV-infected young women in Uganda.
Bark CM; Morrison CS; Salata RA; Byamugisha JK; Katalemwa NH; Mugerwa RD; Mukasa JB; Musoke RN; Nankya-Mutyoba J; Rwambuya S; Walker CJ; Johnson JL
Int J Tuberc Lung Dis; 2010 Dec; 14(12):1647-9. PubMed ID: 21144254
[TBL] [Abstract][Full Text] [Related]
15. QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients.
Khawcharoenporn T; Phetsuksiri B; Rudeeaneksin J; Srisungngam S; Apisarnthanarak A
Jpn J Infect Dis; 2017 Sep; 70(5):502-506. PubMed ID: 28367883
[TBL] [Abstract][Full Text] [Related]
16. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
Schein YL; Madebo T; Andersen HE; Arnesen TM; Dyrhol-Riise AM; Tveiten H; White RA; Winje BA
BMC Infect Dis; 2018 Nov; 18(1):587. PubMed ID: 30453946
[TBL] [Abstract][Full Text] [Related]
17. Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania.
Shayo GA; Moshiro C; Aboud S; Bakari M; Mugusi FM
BMC Infect Dis; 2015 Aug; 15():368. PubMed ID: 26306511
[TBL] [Abstract][Full Text] [Related]
18. [Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients].
Rivero A; López-Cortés L; Castillo R; Verdejo J; García MA; Martínez-Marcos FJ; Díez F; Escribano JC; Canueto J; Lozano F; Pasquau J; Hernández JJ; Márquez M; Kindelán JM;
Enferm Infecc Microbiol Clin; 2007 May; 25(5):305-10. PubMed ID: 17504683
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis treatment outcome and its associated factors among people living with HIV and AIDS in Fako Division of Cameroon.
Tanue EA; Nsagha DS; Njamen TN; Assob NJC
PLoS One; 2019; 14(7):e0218800. PubMed ID: 31361755
[TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.
MMWR Recomm Rep; 1998 Oct; 47(RR-20):1-58. PubMed ID: 9809743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
